Sign inJoin waitlistJoin the waitlist

Yovanni Casablanca

Medical Director, Department of Obstetrics & Gynecology, David Grant Medical Center 2007-2009 · National Capital Consortium

Credentials: · · · · ·

History

Department of Obstetrics & Gynecology · National Capital Consortium
Present
Wake Forest University Baptist Medical Center
Present
National Capital Consortium
Present

American College of Obstetricians & Gynecologists
2017–2018
Obstetrics and Gynecology
Wright State University Boonshoft School of Medicine
2013–2017
Gynecologic Oncology
National Capital Consortium
2009–2013
Family Medicine
David Grant Medical Center
2006–2009
Obstetrics and Gynecology
San Antonio Uniformed Services Health Education Consortium
2002–2006
Uniformed Services Univ of the Hlth Sci, F Edward Hebert Sch of Med
1998–2002
Duke University 1994-1998
1994–1998
Duke University Hospital
1994–1998

Research

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
Cell Reports · 2020 · 87 citations
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study
Gynecologic Oncology · 2021 · 71 citations
Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis
Gynecologic Oncology · 2021 · 49 citations

GM
George Maxwell
29 papers
Chad Hamilton
14 papers
Craig Shriver
14 papers
John Chan
10 papers
CT
Christopher Tarney
9 papers · 1 as a fellow
CR
Christine Rojas
7 papers · 6 as a fellow
NP
Neil Phippen
7 papers
Daniel Kapp
6 papers
Krishnansu Tewari
5 papers
Michael Richardson
5 papers · 5 as a resident
Matthew Powell
4 papers
Nathaniel Jones
4 papers

Clinical trials

Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
Study chair · Not yet recruiting · Phase 2
GOG Foundation
2026–2029
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030